StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > OTCQB

<< Previous

Bullboard Posts

Next >>

Comment by capebretongirlon May 26, 2021 10:05am

85 Views

Post# 33267018

RE:RE:RE:RE:OTCQB

Agree completely Nails - this is yet another positive development and any added exposure to the US investor base is a plus. The ducks are starting to line up and eventually this will take root.

Nailbiter1 wrote:

Hey CBG.
IR reached out re: OTC.

Every exchange is open to shorting activity. Especially with online trading. Look at GameStop as an example. They are listed on the NYSE.

Being on the OTC Platform is more about attracting US investors and the right kind of investors. They will better understand our revenue model as people pay for health care in the US. It seems that many of our Canadian shareholders haven't really grasped this and therefore can't really see the opportunity that we have. The US also seems to have better support for life sciences companies.

Finally, we will be in good company on the OTC, Roche is listed on the OTC.

capebretongirl wrote: Looks like listing on the OTCQB will not present many challenges. Its a long way from the NAS but at least a start giving us more exposure to US investors.

Yes, the sp is horrific, however we can't deny that Tripp has been active in rolling out our message - I am awaiting an NR on the promo team and what it can do for us. In the interim I believe most agree we are oversold and that .88 would be more reflective of where we are today - something has to give shortly.

davewho wrote: We've designed our markets to support informed and efficient trading for all companies in the public markets. Our goal is to allow you to focus on growing your business - while having access to additional resources, capital formation, liquidity and visibility. Upgrading to our OTCQX or OTCQB market demonstrates your commitment to investors by giving them access to the most current information possible while reducing the trading limits and restrictions companies may face on the Pink Market.
Market 101 | OTC Markets